Ozmosi | Perospirone Drug Profile

Product Description

Mechanisms of Action: D2 Antagonist, 5-HT2A Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Enhua Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Depressive Disorder

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
CTR20252231	CTR20252231	N/A	Completed	Schizophrenia	2025-09-09	2025-11-23	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20244956	CTR20244956	N/A	Completed	Schizophrenia	2025-05-27	2025-06-17	Patient Enrollment\|Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20242697	CTR20242697	N/A	Completed	Schizophrenia	2024-11-05	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20241052	CTR20241052	N/A	Completed	Schizophrenia	2024-09-24	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
ChiCTR2200063354	ChiCTR2200063354	N/A	Not yet recruiting	Depressive Disorder, Major	2023-12-31
ChiCTR2200063355	ChiCTR2200063355	N/A	Recruiting	Schizophrenia	2023-12-31
CTR20222399	CTR20222399	N/A	Completed	Schizophrenia	2023-03-03	2025-04-29	Patient Enrollment\|Treatments
CTR20221170	CTR20221170	N/A	Completed	Schizophrenia	2022-09-06	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20220126	CTR20220126	N/A	Completed	Schizophrenia	2022-03-02	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20212498	CTR20212498	N/A	Completed	Schizophrenia	2021-11-24	2025-04-29	Patient Enrollment\|Treatments
CTR20253333	CTR20253333	N/A	Not yet recruiting	Schizophrenia	None	2025-08-20	Treatments
NCT04826510	NCT04826510	P4	Unknown status	Depressive Disorder	2021-06-30	2022-09-03

Recent News Events

Date	Type	Title
04/25/2024	PubMed	Continuous alcohol withdrawal delirium and physical illness-associated delirium in a man brought to the emergency department after a disaster: A case report.
03/18/2024	PubMed	The effective perospirone augmentation with clonazepam for treatment-resistant burning mouth syndrome: A case report.
12/01/2023	PubMed	Therapeutic drug monitoring of perospirone: The lowest effective plasma concentration in patients with schizophrenia.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Perospirone

Alternative Names: perospirone, lullan Clinical Status: Inactive Latest Update: 2024-04-25 Latest Update Note: PubMed Publication